Holen Sie sich die Stockscreener-App
53.27
0.74%
0.39
Schlusskurs vom Vortag:
$52.88
Offen:
$53.77
24-Stunden-Volumen:
1.38M
Relative Volume:
0.79
Marktkapitalisierung:
$134.01B
Einnahmen:
$53.04B
Nettoeinkommen (Verlust:
$4.93B
KGV:
16.79
EPS:
3.1735
Netto-Cashflow:
$15.63B
1W Leistung:
-1.97%
1M Leistung:
-7.05%
6M Leistung:
+6.48%
1J Leistung:
+14.98%
1-Tages-Spanne:
$53.10
$53.77
1-Wochen-Bereich:
$52.40
$54.66
52-Wochen-Spanne:
$45.00
$58.97
Sanofi Adr Stock (SNY) Company Profile
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-26 | Bestätigt | Argus | Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Herabstufung | Stifel | Buy → Hold |
| 2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Herabstufung | UBS | Buy → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
| 2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Eingeleitet | Bernstein | Outperform |
| 2019-08-14 | Hochstufung | UBS | Neutral → Buy |
| 2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
| 2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-03-23 | Hochstufung | Liberum | Hold → Buy |
| 2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes
Here’s Why Mastercard Incorporated (NYSE: MA) Is An Attractive Investment Right Now - Stocks Register
Weekly Upgrades and Downgrades - InvestorPlace
16 New 4-Star Stocks - Morningstar
Sanofi SA (ADR: SNY) Stock Price Could Reach $63: Morningstar Research - TopNews India
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - MSN
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat - Investor's Business Daily
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
Sanofi, HCA, Colgate-Palmolive lead Friday's earnings lineup - Investing.com
Sanofi, HCA, Colgate-Palmolive lead Friday's earnings lineup By Investing.com - Investing.com UK
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI - GlobeNewswire Inc.
Sanofi Deal Jitters Imperil Stock’s Big Rebound - MSN
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale - Zacks Investment Research
Proactive news headlines: Ananda, Helix Exploration, Deltic, Light Science Technologies and more - Proactive Investors UK
French govt set to take stake in Sanofi unit after PE sale - Proactive Investors Australia
Sanofi Negotiating Exclusively With CD&R For Opella 50% Stake Sale - Barchart
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Sanofi ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Ratios Reveal: Breaking Down Sanofi ADR (SNY)’s Financial Health - The Dwinnex
EXK (Endeavour Silver Corp.) may reap gains as insiders became active recently - Knox Daily
Checking in on Clear Channel Outdoor Holdings Inc. (CCO) after recent insiders movement - Knox Daily
Investing in Sanofi ADR (SNY): What You Must Know - Knox Daily
Investing in Replimune Group Inc (REPL) Is Getting More Attractive - Knox Daily
An Analysis of KE Holdings Inc ADR (BEKE)’s Potential Price Growth - Knox Daily
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
OTC Drug and Dietary Supplement Market Opportunities and Strategies to 2033 - GlobeNewswire Inc.
The SNY Stock Puzzle: Unraveling Sanofi ADR’s Fluctuating Performance - The InvestChronicle
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent - Investor's Business Daily
Buy These 5 Big Drug Stocks To Boost Your Portfolio's Health - Barchart
Company’s Banking Stock: Dissecting a 21.83% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Sanofi Stock Up Almost 23% In 3 Months: Buy, Sell Or Hold? - Barchart
Ratio Analysis: Unpacking Sanofi ADR (SNY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Market Analysts see Sanofi ADR [SNY] gaining to $60. Time to buy? - The DBT News
India Insulin Delivery Devices Market Size & Outlook, 2030 - Grand View Research
Sanofi ADR Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):